Capricor Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Capricor Therapeutics Inc CAPR.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of seven analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -40 cents to 8 cents per share.

• Revenue fell 7.9% to $11.13 million from a year ago; analysts expected $5.68 million.

• Capricor Therapeutics Inc's reported EPS for the quarter was a loss of 16 cents​.

• The company reported a quarterly loss of $7.12 million.

• Capricor Therapeutics Inc shares had fallen by 15.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Capricor Therapeutics Inc is $40.00

This summary was machine generated from LSEG data March 19 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)